In the News

June 8, 2023 Mrs. Rosalynn Carter c/o The Carter Center 453 John Lewis Freedom Parkway NE Atlanta, GA 30307-1406 Dear Mrs. Carter: I read with heartfelt interest the news announcing your dementia diagnosis. Thank you for sharing this news so bravely and publicly. Receiving a dementia or Alzheimer’s diagnosis, and how that news impacts a […]

GAP President John Dwyer was quoted in the Washington Post on the CMS decision. The Centers for Medicare and Medicaid Services said it would cover a class of Alzheimer’s drugs that includes Leqembi if the medicines get traditional approval by drug regulators. (Eisai/Reuters) Medicare officials outlined plans Thursday to broadly cover a new class of […]

News that the U.S. Centers for Medicare and Medicaid Services (CMS) will provide broader coverage for Alzheimer’s treatments lacks specifics; unclear if rural and non-hospital based physicians can participate Statement attributed to John M. Dwyer, President of the Global Alzheimer’s Platform Foundation: (WASHINGTON, DC, JUNE 1) — “It’s too early to celebrate. The U.S. Centers […]

Americans want Congress and the president to step in if CMS doesn’t change its restrictive coverage policy. WASHINGTON (May 23, 2023) — Nearly nine in ten voters favor (87% favor, 77% strongly favor) requiring Medicare to cover the cost of FDA-approved drugs that can slow the progression of Alzheimer’s disease, according to a new poll […]

GAP-Net Site The Alzheimer’s Disease Research Center of Albany is looking for volunteers for their research studies. ALBANY — The Alzheimer’s Disease  Research Center of Albany is looking for volunteers for an Alzheimer’s clinical study, putting an emphasis on the recruitment of people of color.  While people from underrepresented communities — including those who are […]

WASHINGTON, DC, May 3, 2023 — Following the announcement of Eli Lilly’s Phase 3 results on a study evaluating donanemab for the treatment of Alzheimer’s disease, Global Alzheimer’s Platform Foundation® (GAP) President John Dwyer said, “Today’s announcement is good news. After waiting nearly 20 years for a new treatment for Alzheimer’s, Alzheimer’s patients and their doctors […]

House Energy & Commerce Subcommittee Tells CMS: Fix Alzheimer’s Drug Coverage WASHINGTON, DC (April 27, 2023) – The Global Alzheimer’s Platform Foundation®(GAP) President John Dwyer commends the strong, bipartisan leadership shown yesterday by U.S. Reps. Brett Guthrie (R-KY) and Anna Eshoo (D-CA) for admonishing the U.S. Centers for Medicare and Medicaid Services (CMS) administrator Chiquita […]

2022 Citizen Scientist Champion Award Elevated Honoree, Bob Deady, was featured in the KU ADRC publication for his dedication to Alzheimer’s research. There’s a familiar face around the University of Kansas Alzheimer’s Disease Research Center (KU ARDC). He doesn’t have an office, or a nameplate on the door or letters behind his name. But he’s doing his […]

GAP President John Dwyer wrote an op-ed in the Dallas Examiner calling on President Biden to reverse the Centers for Medicare and Medicaid Services to cover Leqembi and future Alzheimer’s drugs and treatments. The Biden administration has a big problem on its hands. It’s sending mixed signals on new Food and Drug Administration approved Alzheimer’s […]

by Barbara Campos – Telemundo According to the conclusions of a new Alzheimer’s Association report, Hispanics are almost twice as at risk as other demographic groups, and caring for patients can place a heavy burden on households. The report illustrates the need to allocate more resources and efforts to raise awareness about a degenerative disease […]

“GAP strongly encourages ICER to revamp its model to accurately reflect Leqembi’s benefits and what matters most to patients and their families” For immediate release: Washington, D.C. (March 17, 2023) — Joining other Alzheimer’s advocates, experts and researchers, Global Alzheimer’s Platform Foundation® (GAP) President John Dwyer provided written comments as part of the Institute for […]

“Today, the Veterans Health Administration (VA) demonstrated enormous leadership and concern for the health of veteran’s fighting Alzheimer’s disease with its decision to cover the cost of Leqembi.  Our veterans battled for us, and the VA is now giving their patients new therapies to battle Alzheimer’s.” Statement by Global Alzheimer’s Platform Foundation® President John Dwyer: […]

BAY VILLAGE, Ohio — There are two newly-approved treatments to treat Alzheimer’s Disease, but getting them covered by medicare is a battle. Alzheimer’s impacts nearly 6 million Americans over the age of 65, and that number is expected to triple by 2060. It is the sixth leading cause of death in the U.S., according to […]

Statement by Global Alzheimer’s Platform Foundation® President John Dwyer: Washington, D.C. (Feb. 27, 2023) — “On behalf of the of the thousands of trial participants, clinicians and researchers who are part of the Global Alzheimer’s Platform Foundation (GAP) network, we want to thank and honor Dr. Billy Dunn for his leadership and scientific contributions, which […]

“CMS’s latest decision on disease-modifying therapies for Alzheimer’s patients is effectively a coverage denial for this entire class of drugs, and patients will needlessly die as a result of it.” Statement by Global Alzheimer’s Platform Foundation® President John Dwyer: Washington, D.C. (Feb. 23, 2023) — “Once again, the Centers for Medicare and Medicaid Services (CMS) […]

The Global Alzheimer’s Platform Foundation’s® (GAP) 2022 Citizen Scientist Award recipients include the first husband-and-wife volunteer team, an Alzheimer’s advocate who champions participation in prevention studies, and a Parkinson’s disease clinical trial participant who volunteers in research studies to find hope after diagnosis  WASHINGTON, DC (Feb. 22, 2023) — Today, the Global Alzheimer’s Platform Foundation […]

The Global Alzheimer’s Platform Foundation® adds Lammert Albers to its team in the role of chief commercial officer; he joins GAP with leadership experience in growing clinical trial and life science technology companies WASHINGTON, DC (Feb. 21, 2023) — The Global Alzheimer’s Platform Foundation (GAP) welcomes Lammert Albers to its leadership team. Lammert has successfully […]

“With this approval, it is incumbent on Center for Medicare and Medicaid Services (CMS) Administrator Chiquita Brooks-LaSure and the drug’s sponsors to offer this life-changing therapy to patients quickly, while prioritizing access and economic fairness.” Statement attributed to Global Alzheimer’s Platform Foundation President John Dwyer: Washington, D.C. (Jan. 6, 2023) — We applaud the Food […]

GAP Associate Director of Recruitment & Strategic Initiatives, Dr. Tamiko MaGee Rodgers, was featured on the Roland Martin Unfiltered Daily Digital Show and spoke about Alzheimer’s disease clinical trials.

Washington, DC — December 23, 2022–Appropriations bills are not simply about funding. They are about people. That is why we are grateful that Congress prioritized funding for accelerated and disruptive Alzheimer’s disease research in the 2023 Omnibus Appropriations Bill. Increases in funding for the Advanced Research Projects Agency for Health (ARPA-H) and the National Institutes […]

Washington, DC — December 23, 2022–The Institute for Clinical and Economic Review (ICER) has again failed in its attempt to value the benefit provided by a new, life-improving Alzheimer’s treatment, threatening millions of Americans who are living with Alzheimer’s disease. The report, “Beta-Amyloid Antibodies for Early Alzheimer’s Disease,” released yesterday, advances an analytical framework that […]

Washington, D.C. (Nov. 30, 2022) – “Following the positive, detailed results from Eisai on lecanemab, a monoclonal antibody therapy for the treatment of Alzheimer’s, there is every reason for the Alzheimer’s community to have optimism today. Thanks to the unwavering commitment of Eisai, its clinical trial partners, and most importantly, the people who participated in […]

GAP President John Dwyer spoke with Cathy Kelly of Pink Sheet about the Bio-Hermes study, the necessity for diversity in #Alzheimers clinical trials, and how industry-sponsored trials are out pacing government-sponsored trials.  Although Alzheimer’s stakeholders are dismayed by the treatment access restrictions imposed by the Medicare national coverage determination last spring, the policy has also jumpstarted […]